HROW - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Mar 2, 2026

5.0/10

Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Strategic initiatives include sales force expansion, acquisition of Melt Pharmaceuticals, patient access programs, and transitioning ImprimisRx customers to FDA-approved products, alongside new product launches like BYQLOVI and BYOOVIZ.. The acquisition of Melt Pharmaceuticals carries significant contingent liabilities, with potential payments of up to $87.2 million upon FDA approval and an additional $260 million tied to sales milestones.. Branded segment revenue increased significantly by 68.6%.

Top Concerns

!Significant upfront and milestone payments for acquired product rights are treated as capitalized assets, increasing the potential for future impairments if projections are not met.
!Large reserves for sales deductions and returns are subject to significant management judgment and could be adjusted to influence earnings.
!The acquisition of Melt Pharmaceuticals carries significant contingent liabilities, with potential payments of up to $87.2 million upon FDA approval and an additional $260 million tied to sales milestones.
!A $11.2 million judgment against OSRX for trademark infringement is pending appeal, and no amount has been recognized due to collection uncertainty.
!Cyberattack and IT System Breach (high)

Top Positives

+Company is shifting focus towards branded products (IHEEZO, VEVYE) with increased marketing efforts, while ImprimisRx revenue is declining due to lower volume.
+Operating cash flow improved significantly in 2025 due to better operating results and collections, recovering from a cash usage in 2024 largely driven by working capital changes and extended distributor terms.
+While management expresses confidence in near-term liquidity, significant future financing needs are acknowledged due to potential acquisitions and growth ambitions.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

6.0/10

Management tone is confidently optimistic with focus on increase in sales and units sold of iheezo and vevye.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

6.0/10

Earnings quality shows aggressive accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is moderate with $278,249,000 in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows cyberattack and it system breach as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

6.0/10

Segment health analysis shows Branded as strongest performer while ImprimisRx lags.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.